These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas. Komminoth P. Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671 [Abstract] [Full Text] [Related]
3. The RET proto-oncogene and cancer. Donis-Keller H. J Intern Med; 1995 Oct; 238(4):319-25. PubMed ID: 7595167 [Abstract] [Full Text] [Related]
4. Mutations in the cysteine-rich region of the RET proto-oncogene in patients diagnosed as having sporadic medullary thyroid carcinoma. Kimura T, Yoshimoto K, Yokogoshi Y, Saito S. Endocr J; 1995 Aug; 42(4):517-25. PubMed ID: 8556059 [Abstract] [Full Text] [Related]
5. Molecular and biochemical screening for the diagnosis and management of medullary thyroid carcinoma in multiple endocrine neoplasia type 2A. Vieira AE, Mello MP, Elias LL, Lau IF, Maciel LM, Moreira AC, Castro M. Horm Metab Res; 2002 Apr; 34(4):202-6. PubMed ID: 11987030 [Abstract] [Full Text] [Related]
6. [Early diagnosis of multiple endocrine neoplasia type 2 (MEN 2) by detection of mutated RET proto-oncogene carriers]. Sansó G, Domené HM, Iorcansky S, Barontini M. Medicina (B Aires); 1998 Apr; 58(2):179-84. PubMed ID: 9706252 [Abstract] [Full Text] [Related]
7. Mutation analysis of the RET proto-oncogene in Dutch families with MEN 2A, MEN 2B and FMTC: two novel mutations and one de novo mutation for MEN 2A. Landsvater RM, Jansen RP, Hofstra RM, Buys CH, Lips CJ, Ploos van Amstel HK. Hum Genet; 1996 Jan; 97(1):11-4. PubMed ID: 8557249 [Abstract] [Full Text] [Related]
8. Germline mutations of the RET proto-oncogene in pedigree with MEN type 2A: DNA analysis and its implications for pediatric surgery. Shimotake T, Iwai N, Inoue K, Inazawa J, Nishisho I. J Pediatr Surg; 1996 Jun; 31(6):779-81. PubMed ID: 8783101 [Abstract] [Full Text] [Related]
10. Familial medullary thyroid carcinoma: not a distinct entity? Genotype-phenotype correlation in a large family. Moers AM, Landsvater RM, Schaap C, Jansen-Schillhorn van Veen JM, de Valk IA, Blijham GH, Höppener JW, Vroom TM, van Amstel HK, Lips CJ. Am J Med; 1996 Dec; 101(6):635-41. PubMed ID: 9003111 [Abstract] [Full Text] [Related]
11. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Eng C, Smith DP, Mulligan LM, Nagai MA, Healey CS, Ponder MA, Gardner E, Scheumann GF, Jackson CE, Tunnacliffe A. Hum Mol Genet; 1994 Feb; 3(2):237-41. PubMed ID: 7911697 [Abstract] [Full Text] [Related]
12. Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene mutations. Kambouris M, Jackson CE, Feldman GL. Hum Mutat; 1996 Feb; 8(1):64-70. PubMed ID: 8807338 [Abstract] [Full Text] [Related]
13. Absence of mutations in the MEN2A region of the ret proto-oncogene in non-MEN 2A phaeochromocytomas. Chew SL, Lavender P, Jain A, Weber A, Ross RJ, Wass JA, Besser GM, Clark AJ. Clin Endocrinol (Oxf); 1995 Jan; 42(1):17-21. PubMed ID: 7889627 [Abstract] [Full Text] [Related]
14. [Detection of RET-proto-oncogene mutations in the diagnosis of Type 2 endocrine neoplasia (MEN 2)]. Komminoth P, Muletta-Feurer S, Soltermann A, Gemsenjäger E, Bürgi H, Staub JJ, Schönle E, Fried M, Vetter W, Spinas GA, Heitz PU. Schweiz Med Wochenschr; 1996 Aug 06; 126(31-32):1329-38. PubMed ID: 8765374 [Abstract] [Full Text] [Related]
15. A rare missense variant in RET exon 8 in a Portuguese family with atypical multiple endocrine neoplasia type 2A. Martins AF, Martins JM, do Vale S, Dias T, Silveira C, da Silva IR, Carmo-Fonseca M. Hormones (Athens); 2016 Jul 06; 15(3):435-440. PubMed ID: 27838608 [Abstract] [Full Text] [Related]
16. Mutational analysis of the RET proto-oncogene in 71 Japanese patients with medullary thyroid carcinoma. Shirahama S, Ogura K, Takami H, Ito K, Tohsen T, Miyauchi A, Nakamura Y. J Hum Genet; 1998 Jul 06; 43(2):101-6. PubMed ID: 9621513 [Abstract] [Full Text] [Related]
17. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers. Sanso GE, Domene HM, Garcia R, Pusiol E, de M, Roque M, Ring A, Perinetti H, Elsner B, Iorcansky S, Barontini M. Cancer; 2002 Jan 15; 94(2):323-30. PubMed ID: 11900218 [Abstract] [Full Text] [Related]
18. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas. Komminoth P, Kunz EK, Matias-Guiu X, Hiort O, Christiansen G, Colomer A, Roth J, Heitz PU. Cancer; 1995 Aug 01; 76(3):479-89. PubMed ID: 8625130 [Abstract] [Full Text] [Related]
19. Presymptomatic DNA screening in families with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma. Frilling A, Dralle H, Eng C, Raue F, Broelsch CE. Surgery; 1995 Dec 01; 118(6):1099-103; discussion 1103-4. PubMed ID: 7491529 [Abstract] [Full Text] [Related]
20. Clinical characteristics and genetic screening of an extended family with MEN2A. Algün E, Abaci N, Kösem M, Kotan C, Köseoğlu B, Boztepe H, Sekeroğlu R, Aslan H, Topal C, Ayakta H, Uygan I, Alagöl F, Erginel-Unaltuna N, Aksoy H. J Endocrinol Invest; 2002 Dec 01; 25(7):603-8. PubMed ID: 12150334 [Abstract] [Full Text] [Related] Page: [Next] [New Search]